DURHAM, N.C., May 4, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc., a Delaware corporation (Nasdaq:OXBT) (the “Company”), announced today that it entered into purchase agreements with certain institutional investors for the sale of 1,724,138 shares of its common stock and warrants to purchase 732,758 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.425 share of common stock at a price of $2.90 per unit. The warrants have a term of five years and an exercise price of $5.32 per share.
